NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 36, 2015, Pages 11318-11323

  Hu, Changyun ^a   Ding, Heyuan ^a,b   Li, Yangyang ^a   Pearson, James A ^a   Zhang, Xiaojun ^a   Flavell, Richard A ^c   Wong, F Susan ^d   Wen, Li ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

^c YALE UNIVERSITY   (United States)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Chemokine; Islet; NLRP3; NOD mouse; Type 1 diabetes

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CRYOPYRIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; RANTES; CARRIER PROTEIN; CCR5 PROTEIN, MOUSE; CXCR3 PROTEIN, MOUSE; INFLAMMASOME; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA; NLRP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; LEUCINE RICH REPEAT AND PYRIN DOMAINOR CONTAINING PROTEIN 3 DEFICIENCY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL MOTION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TIME FACTOR;

ADOPTIVE TRANSFER; ANIMALS; CARRIER PROTEINS; CELL MOVEMENT; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOTAXIS; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; HUMANS; INFLAMMASOMES; INTERFERON REGULATORY FACTOR-1; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RECEPTORS, CCR5; RECEPTORS, CXCR3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS;

EID: 84941254145     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1513509112     Document Type: Article

References (38)

1. Herold KC, et al. (1992) Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41(3):385-391.
2. Herold KC, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346(22):1692-1698.
3. Hu CY, et al. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117(12):3857-3867.
4. Pescovitz MD, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143-2152.
5. Kim HS, et al. (2007) Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27(2):321-333.
6. Wen L, et al. (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455(7216):1109-1113.
7. Wong FS, et al. (2008) The role of Toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann N Y Acad Sci 1150:146-148.
8. Filippi CM, et al. (2011) TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur J Immunol 41(5):1399-1409.
9. Tai N, Wong FS, Wen L (2013) TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J Immunol 191(6):2926-2937.
10. Gülden E, et al. (2013) Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice. PLoS One 8(9):e75385.
11. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140(6):821-832.
12. Esser N, et al. (2013) Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 56(11):2487-2497.
13. Vandanmagsar B, et al. (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17(2):179-188.
14. Jourdan T, et al. (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 19(9):1132-1140.
15. Pontillo A, et al. (2012) Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 45(4):271-278.
16. Gris D, et al. (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185(2):974-981.
17. Kolly L, et al. (2009) Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol 183(6):4003-4012.
18. Schott WH, et al. (2004) Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 53(1):99-104.
19. Wen L, et al. (2011) In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18. Eur J Immunol 41(5):1344-1351.
20. Ablamunits V, et al. (2012) Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: Evidence of improved immune regulation. Diabetes 61(1):145-154.
21. Magitta NF, et al. (2009) A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun 10(2):120-124.
22. Pontillo A, et al. (2010) Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43(8):583-589.
23. Guarda G, et al. (2011) Differential expression of NLRP3 among hematopoietic cells. J Immunol 186(4):2529-2534.
24. Huang Z, et al. (2014) Tissue-specific expression of the NOD-like receptor protein 3 in BALB/c mice. J Vet Sci 15(2):173-177.
25. Sutterwala FS, et al. (2006) Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24(3):317-327.
26. Inoue M, Shinohara ML (2013) NLRP3 Inflammasome and MS/EAE. Autoimmune Dis 2013:859145.
27. Inoue M, Williams KL, Gunn MD, Shinohara ML (2012) NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 109(26):10480-10485.
28. Sarkar SA, et al. (2012) Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 61(2):436-446.
29. Tada Y, Ho A, Matsuyama T, Mak TW (1997) Reduced incidence and severity of antigeninduced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 185(2):231-238.
30. Harikumar KB, et al. (2014) K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 15(3):231-238.
31. Mohamed IN, et al. (2014) Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia 57(2):413-423.
32. Bonecchi R, et al. (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J ExpMed 187(1):129-134.
33. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187(6):875-883.
34. Luster AD, Ravetch JV (1987) Genomic characterization of a gamma-interferoninducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol Cell Biol 7(10):3723-3731.
35. Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18:593-620.
36. Frigerio S, et al. (2002) Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8(12):1414-1420.
37. Oikawa Y, et al. (2003) Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 171(11):5865-5875.
38. Marleau AM, Sarvetnick NE (2011) IL-18 is required for self-reactive T cell expansion in NOD mice. J Autoimmun 36(3-4):263-277.